Michael Weller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3232536/publications.pdf

Version: 2024-02-01

795	98,812	529 127	297 292
papers	citations	h-index	g-index

824	824	824	59158
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine, 2005, 352, 987-996.	27.0	17,395
2	MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine, 2005, 352, 997-1003.	27.0	6,573
3	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, The, 2009, 10, 459-466.	10.7	6,451
4	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
5	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. JAMA - Journal of the American Medical Association, 2017, 318, 2306.	7.4	1,619
6	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 2011, 478, 197-203.	27.8	1,514
7	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 2009, 118, 469-474.	7.7	1,020
8	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, The, 2012, 13, 707-715.	10.7	980
9	Current state of immunotherapy for glioblastoma. Nature Reviews Clinical Oncology, 2018, 15, 422-442.	27.6	873
10	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
11	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	10.7	816
12	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncology, 2020, 6, 1003.	7.1	805
13	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1100-1108.	10.7	800
14	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, The, 2017, 18, 1373-1385.	10.7	776
15	Long-term survival with glioblastoma multiforme. Brain, 2007, 130, 2596-2606.	7.6	748
16	NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 2009, 27, 5874-5880.	1.6	743
17	Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature Medicine, 2002, 8, 808-815.	30.7	741
18	Correlation of O⁶-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. Journal of Clinical Oncology, 2008, 26, 4189-4199.	1.6	725

#	Article	IF	Citations
19	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica, 2010, 120, 707-718.	7.7	719
20	Glioma. Nature Reviews Disease Primers, 2015, 1, 15017.	30.5	718
21	Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 2017, 377, 1954-1963.	27.0	670
22	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncology, The, 2014, 15, e395-e403.	10.7	647
23	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nature Reviews Neurology, 2010, 6, 39-51.	10.1	644
24	EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncology, The, 2016, 17, e383-e391.	10.7	627
25	cIMPACT-NOW update 3: recommended diagnostic criteria for â€œDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IVâ€• Acta Neuropathologica, 2018, 136, 805-810.	7.7	599
26	Standards of care for treatment of recurrent glioblastomaâ€”are we there yet?. Neuro-Oncology, 2013, 15, 4-27.	1.2	592
27	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	10.7	586
28	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	10.7	582
29	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology, 2016, 18, 1199-1208.	1.2	566
30	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
31	Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network. Journal of Clinical Oncology, 2009, 27, 5743-5750.	1.6	534
32	High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncology, The, 2010, 11, 1036-1047.	10.7	530
33	Advances in the molecular genetics of gliomas â€” implications for classification and therapy. Nature Reviews Clinical Oncology, 2017, 14, 434-452.	27.6	497
34	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology, The, 2008, 9, 29-38.	10.7	487
35	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 2015, 17, 1064-1075.	1.2	485
36	MGMT testingâ€”the challenges for biomarker-based glioma treatment. Nature Reviews Neurology, 2014, 10, 372-385.	10.1	454

#	Article	IF	Citations
37	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. Journal of Clinical Oncology, 2010, 28, 1168-1174.	1.6	450
38	Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2010, 28, 2712-2718.	1.6	389
39	Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes. Cell, 2020, 181, 1626-1642.e20.	28.9	388
40	Molecular targeted therapy of glioblastoma. Cancer Treatment Reviews, 2019, 80, 101896.	7.7	386
41	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOAâ€“09): a randomised, open-label, phase 3 trial. Lancet, The, 2019, 393, 678-688.	13.7	384
42	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 2017, 19, 162-174.	1.2	381
43	SD-208, a Novel Transforming Growth Factor Î² Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo. Cancer Research, 2004, 64, 7954-7961.	0.9	380
44	Current concepts and management of glioblastoma. Annals of Neurology, 2011, 70, 9-21.	5.3	380
45	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an â€œintegratedâ€•diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 2015, 129, 133-146.	7.7	378
46	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
47	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine, 2018, 24, 1192-1203.	30.7	359
48	Changing Paradigmsâ€”An Update on the Multidisciplinary Management of Malignant Glioma. Oncologist, 2006, 11, 165-180.	3.7	357
49	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 540-557.	6.4	348
50	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 2015, 17, 1188-98.	1.2	346
51	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	7.7	344
52	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncology, The, 2015, 16, e322-e332.	10.7	340
53	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
54	Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. Clinical Cancer Research, 2008, 14, 2900-2908.	7.0	319

#	Article	IF	Citations
55	Caspases as treatment targets in stroke and neurodegenerative diseases. Annals of Neurology, 1999, 45, 421-429.	5.3	315
56	Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Research, 2003, 63, 7462-7.	0.9	312
57	A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape. Journal of Immunology, 2002, 168, 4772-4780.	0.8	310
58	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	13.7	307
59	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica, 2013, 126, 443-451.	7.7	304
60	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
61	O⁶â€methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. Journal of Neurochemistry, 2006, 96, 766-776.	3.9	290
62	Glioblastoma. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 381-397.	1.8	289
63	Neuroprotection by Hypoxic Preconditioning Requires Sequential Activation of Vascular Endothelial Growth Factor Receptor and Akt. Journal of Neuroscience, 2002, 22, 6401-6407.	3.6	279
64	RNA Interference Targeting Transforming Growth Factor-Î² Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates TumorigenicityIn vivo. Cancer Research, 2004, 64, 7596-7603.	0.9	275
65	Immunosuppressive mechanisms in glioblastoma: Fig. 1.. Neuro-Oncology, 2015, 17, vii9-vii14.	1.2	275
66	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 2012, 124, 547-560.	7.7	274
67	Corticosteroids compromise survival in glioblastoma. Brain, 2016, 139, 1458-1471.	7.6	271
68	Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-Î² and Protein Kinase R Â. Stem Cells, 2009, 27, 909-919.	3.2	268
69	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 2015, 21, 2057-2064.	7.0	264
70	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	7.7	254
71	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathologica, 2015, 129, 679-693.	7.7	254
72	CD95/CD95 Ligand Interactions on Epithelial Cells in Host Defense to Pseudomonas aeruginosa. Science, 2000, 290, 527-530.	12.6	248

#	Article	IF	Citations
73	Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. International Journal of Cancer, 2011, 129, 659-670.	5.1	247
74	Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma. Journal of Clinical Oncology, 2007, 25, 3357-3361.	1.6	237
75	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	7.7	237
76	Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. Journal of Neuro-Oncology, 2001, 53, 177-185.	2.9	231
77	EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncology, 2021, 23, 1821-1834.	1.2	230
78	Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Annals of Neurology, 2003, 54, 388-392.	5.3	226
79	Malignant glioma biology: Role for TGF-? in growth, motility, angiogenesis, and immune escape. Microscopy Research and Technique, 2001, 52, 401-410.	2.2	224
80	ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. International Journal of Oncology, 2014, 44, 1843-1852.	3.3	223
81	Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. International Journal of Cancer, 2012, 131, 1342-1350.	5.1	220
82	EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma. Cancer Cell, 2013, 24, 438-449.	16.8	219
83	Predicting response to cancer chemotherapy: the role of p53. Cell and Tissue Research, 1998, 292, 435-445.	2.9	217
84	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 2013, 81, 1515-1522.	1.1	211
85	Local Fas/APO-1 (CD95) ligand-mediated tumor cell killingin vivo. European Journal of Immunology, 1995, 25, 2253-2258.	2.9	205
86	Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of Neurotoxicity. Biochemical and Biophysical Research Communications, 1999, 265, 479-483.	2.1	197
87	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncology, The, 2017, 18, e330-e340.	10.7	195
88	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathologica, 2018, 136, 793-803.	7.7	195
89	TGF-Â and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain, 2006, 129, 2416-2425.	7.6	194
90	NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. Cancer Research, 2018, 78, 1031-1043.	0.9	193

#	Article	IF	Citations
91	Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-Oncology, 2012, 14, 1481-1484.	1.2	192
92	Invasion patterns in brain metastases of solid cancers. Neuro-Oncology, 2013, 15, 1664-1672.	1.2	191
93	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	7.7	190
94	EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro-Oncology, 2020, 22, 31-45.	1.2	190
95	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastomaâ€"results from the DIRECTOR trial. Neuro-Oncology, 2016, 18, 549-556.	1.2	187
96	Induction of Nitric Oxide Synthase and Nitric Oxideâ€Mediated Apoptosis in Neuronal PC12 Cells After Stimulation with Tumor Necrosis FActorâ€Î±/Lipopolysaccharide. Journal of Neurochemistry, 1998, 71, 88-94.	3.9	186
97	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	1.2	184
98	Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?. Clinical Cancer Research, 2011, 17, 4588-4599.	7.0	179
99	A specific miRNA signature in the peripheral blood of glioblastoma patients. Journal of Neurochemistry, 2011, 118, 449-457.	3.9	177
100	Intratumoral IL-12 combined with CTLA-4 blockade elicits T cellâ€"mediated glioma rejection. Journal of Experimental Medicine, 2013, 210, 2803-2811.	8.5	177
101	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	7.7	176
102	EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro-Oncology, 2018, 20, 445-456.	1.2	173
103	Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell, 2019, 35, 692-704.e12.	16.8	172
104	Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncology, The, 2013, 14, e370-e379.	10.7	167
105	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncology, 2022, 24, 1935-1949.	1.2	165
106	APO2 ligand: a novel lethal weapon against malignant glioma?. FEBS Letters, 1998, 427, 124-128.	2.8	164
107	Therapeutic options in recurrent glioblastomaâ€"An update. Critical Reviews in Oncology/Hematology, 2016, 99, 389-408.	4.4	161
108	Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene, 2000, 19, 4210-4220.	5.9	159

#	Article	IF	Citations
109	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2016, 34, 731-739.	1.6	159
110	MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Research, 2003, 63, 8996-9006.	0.9	158
111	Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations. Clinical Cancer Research, 2013, 19, 5146-5157.	7.0	157
112	PET imaging in patients with meningiomaâ€"report of the RANO/PET Group. Neuro-Oncology, 2017, 19, 1576-1587.	1.2	157
113	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 2012, 14, iv100-iv108.	1.2	154
114	Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. International Journal of Cancer, 1998, 79, 640-644.	5.1	153
115	Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. Journal of Clinical Oncology, 2006, 24, 4412-4417.	1.6	152
116	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 409-414.	7.1	152
117	Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. Clinical Cancer Research, 2017, 23, 6846-6855.	7.0	151
118	Leptomeningeal metastasis: survival and prognostic factors in 155 patients. Journal of the Neurological Sciences, 2004, 223, 167-178.	0.6	150
119	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncology, 2023, 25, 123-134.	1.2	150
120	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell, 2018, 34, 163-177.e7.	16.8	145
121	Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D. Journal of Immunology, 2008, 180, 7338-7348.	0.8	144
122	Biological tumor volume in ¹⁸ FET-PET before radiochemotherapy correlates with survival in GBM. Neurology, 2015, 84, 710-719.	1.1	144
123	New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology, 2009, 11, 69-79.	1.2	142
124	CAMTA1 is a novel tumour suppressor regulated by miR-9/9[*]in glioblastoma stem cells. EMBO Journal, 2011, 30, 4309-4322.	7.8	141
125	PET imaging in patients with brain metastasisâ€"report of the RANO/PET group. Neuro-Oncology, 2019, 21, 585-595.	1.2	139
126	HLA-E Protects Glioma Cells from NKG2D-Mediated Immune Responses In Vitro: Implications for Immune Escape In Vivo. Journal of Neuropathology and Experimental Neurology, 2005, 64, 523-528.	1.7	137

#	Article	IF	Citations
127	Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of Neuro-Oncology, 2010, 96, 393-402.	2.9	137
128	Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant Glioma. Journal of Clinical Oncology, 2003, 21, 3276-3284.	1.6	134
129	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq1 1 0.784314 rgBT /Ove Oncology, The, 2021, 22, 813-823.	10.7	132
130	Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker?. Clinical Cancer Research, 2007, 13, 6933-6937.	7.0	131
131	Epilepsy meets cancer: when, why, and what to do about it?. Lancet Oncology, The, 2012, 13, e375-e382.	10.7	131
132	Optimal management of elderly patients with glioblastoma. Cancer Treatment Reviews, 2013, 39, 350-357.	7.7	131
133	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro-Oncology, 2020, 22, 757-772.	1.2	131
134	Transforming Growth Factors Î²1 (TGF-Î²1) and TGF-Î²2 Promote Glioma Cell Migration via Up-Regulation of Î±VÎ²3 Integrin Expression. Biochemical and Biophysical Research Communications, 2000, 268, 607-611.	2.1	130
135	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 2016, 18, now133.	1.2	130
136	Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects. Clinical Cancer Research, 2014, 20, 5612-5619.	7.0	129
137	Neutrophils Obstructing Brain Capillaries Are a Major Cause of No-Reflow in Ischemic Stroke. Cell Reports, 2020, 33, 108260.	6.4	129
138	Fas/CD95/Apo-I activates the acidic sphingomyelinase via Caspases. Cell Death and Differentiation, 1998, 5, 29-37.	11.2	128
139	Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide. Journal of Clinical Oncology, 2009, 27, 1257-1261.	1.6	128
140	Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica, 2010, 120, 585-592.	7.7	127
141	Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness. Clinical Cancer Research, 2012, 18, 105-117.	7.0	126
142	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-Oncology, 2020, 22, 684-693.	1.2	126
143	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071.		126
144	GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas. Clinical Cancer Research, 2010, 16, 3851-3859.	7.0	125

#	Article	IF	Citations
145	Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nature Reviews Neurology, 2017, 13, 363-374.	10.1	125
146	Transforming growth factor-Î²2 induces apoptosis of murine T cell clones without down-regulatingbcl-2 mRNA expression. European Journal of Immunology, 1994, 24, 1293-1300.	2.9	122
147	Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncology, 2011, 13, 566-579.	1.2	121
148	Expression pattern of the water channel aquaporin-4 in human gliomas is associated with bloodâ€“brain barrier disturbance but not with patient survival. Journal of Neuroscience Research, 2007, 85, 1336-1346.	2.9	120
149	Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Journal of Neurochemistry, 2012, 122, 444-455.	3.9	120
150	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	7.7	120
151	Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma. PLoS ONE, 2012, 7, e33449.	2.5	120
152	Transforming Growth Factor-β: A Molecular Target for the Future Therapy of Glioblastoma. Current Pharmaceutical Design, 2006, 12, 341-349.	1.9	119
153	How did lomustine become standard of care in recurrent glioblastoma?. Cancer Treatment Reviews, 2020, 87, 102029.	7.7	119
154	Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 2014, 135, 1822-1831.	5.1	117
155	Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-Â-dependent HIF-1Â-mediated induction of CXCL12. Brain, 2006, 129, 2426-2435.	7.6	116
156	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathologica, 2020, 140, 409-413.	7.7	116
157	Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death and Differentiation, 1999, 6, 370-376.	11.2	115
158	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology, 2019, 21, 26-36.	1.2	114
159	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro-Oncology, 2019, 21, 571-584.	1.2	114
160	PTEN methylation and expression in glioblastomas. Acta Neuropathologica, 2003, 106, 479-485.	7.7	113
161	Bevacizumab and Recurrent Malignant Gliomas: A European Perspective. Journal of Clinical Oncology, 2010, 28, e188-e189.	1.6	112
162	Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. Journal of Neurochemistry, 2005, 93, 992-999.	3.9	111

#	Article	IF	Citations
163	Glucocorticoid treatment of primary CNS lymphoma. , 1999, 43, 237-239.		110
164	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathologica Communications, 2017, 5, 39.	5.2	110
165	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O⁶-Methylguanineâ€“DNA Methyltransferase Biomarker Analyses. Journal of Clinical Oncology, 2017, 35, 343-351.	1.6	110
166	Molecular determinants of glioma cell migration and invasion. Journal of Neurosurgery, 2001, 94, 978-984.	1.6	109
167	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica, 2018, 135, 955-963.	7.7	109
168	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro-Oncology, 2020, 22, 1262-1275.	1.2	109
169	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 2017, 19, 1119-1126.	1.2	107
170	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	7.0	105
171	CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene, 2001, 20, 4128-4137.	5.9	104
172	PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene, 1999, 18, 3936-3943.	5.9	102
173	Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. International Journal of Cancer, 2014, 134, 2437-2447.	5.1	100
174	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro-Oncology, 2017, 19, 614-624.	1.2	100
175	Highâ€throughput proteomic analysis of <scp>FFPE</scp> tissue samples facilitates tumor stratification. Molecular Oncology, 2019, 13, 2305-2328.	4.6	100
176	Both the Neuronal and Inducible Isoforms Contribute to Upregulation of Retinal Nitric Oxide Synthase Activity by Brain-Derived Neurotrophic Factor. Journal of Neuroscience, 1999, 19, 8517-8527.	3.6	98
177	Cilengitide: an RGD pentapeptide Î±Î½Î²3 and Î±Î½Î²5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncology, 2011, 7, 339-354.	2.4	98
178	Processing of Immunosuppressive Pro-TGF-Î²1,2 by Human Glioblastoma Cells Involves Cytoplasmic and Secreted Furin-Like Proteases. Journal of Immunology, 2001, 166, 7238-7243.	0.8	97
179	Evidence-based recommendations on categories for extent of resection in diffuse glioma. European Journal of Cancer, 2021, 149, 23-33.	2.8	97
180	Cooperative Interception of Neuronal Apoptosis by BCLâ€2 and BAGâ€1 Expression: Prevention of Caspase Activation and Reduced Production of Reactive Oxygen Species. Journal of Neurochemistry, 1997, 69, 2075-2086.	3.9	94

#	Article	IF	Citations
181	Integrin control of the transforming growth factor-Î² pathway in glioblastoma. Brain, 2013, 136, 564-576.	7.6	94
182	Î±vâ€‰integrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer, 2013, 133, 2362-2371.	5.1	94
183	Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 2015, 84, 1242-1248.	1.1	94
184	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncology, 2017, 19, 12-21.	1.2	94
185	MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. Clinical Cancer Research, 2019, 25, 1809-1816.	7.0	94
186	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro-Oncology, 2020, 22, 17-30.	1.2	94
187	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death and Differentiation, 1998, 5, 847-857.	11.2	93
188	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	1.6	93
189	Rechallenge with temozolomide in patients with recurrent gliomas. Journal of Neurology, 2009, 256, 734-741.	3.6	92
190	Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time. Scientific Reports, 2018, 8, 4984.	3.3	91
191	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro-Oncology, 2019, 21, 648-658.	1.2	90
192	BCLâ€‰2 promotes migration and invasiveness of human glioma cells. FEBS Letters, 1998, 440, 419-424.	2.8	89
193	Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. Glia, 2003, 42, 379-389.	4.9	89
194	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. Clinical Cancer Research, 2020, 26, 5287-5296.	7.0	88
195	Chemotherapy of human malignant glioma. Neurology, 1997, 48, 1704-1709.	1.1	87
196	Malignant Glioma Cells Counteract Antitumor Immune Responses through Expression of Lectin-Like Transcript-1. Cancer Research, 2007, 67, 3540-3544.	0.9	87
197	Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-Î²2. Journal of Neuroscience, 2001, 21, 3360-3368.	3.6	85
198	Steroids in neurooncology: actions, indications, side-effects. Current Opinion in Neurology, 2010, 23, 597-602.	3.6	85

#	Article	IF	Citations
199	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-? release and reduces migration and invasiveness of human malignant glioma cells. International Journal of Cancer, 2001, 93, 53-61.	5.1	84
200	Transforming growth factor-Î² pathway activity in glioblastoma. Oncotarget, 2015, 6, 5963-5977.	1.8	84
201	Gliomatosis cerebri: Molecular pathology and clinical course. Annals of Neurology, 2002, 52, 390-399.	5.3	83
202	Targeting integrins in malignant glioma. Targeted Oncology, 2010, 5, 175-181.	3.6	83
203	Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications. Journal of Neuro-Oncology, 2004, 70, 245-254.	2.9	82
204	Inhibiting TGF-Î² signaling restores immune surveillance in the SMA-560 glioma model. Neuro-Oncology, 2007, 9, 259-270.	1.2	82
205	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biology, 2015, 16, 16.	8.8	82
206	⁶⁸Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?. Neuro-Oncology, 2016, 18, 1021-1027.	1.2	80
207	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncology, The, 2018, 19, 1170-1179.	10.7	80
208	Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Research, 2002, 62, 1915-9.	0.9	80
209	Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-Oncology, 2009, 11, 747-756.	1.2	79
210	Epidermal growth factor receptor. Current Opinion in Neurology, 2012, 25, 774-779.	3.6	79
211	Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to⁶⁸Ga-DOTATATE/-TOC uptake. Neuro-Oncology, 2016, 18, now060.	1.2	79
212	Biological activity of tumor-treating fields in preclinical glioma models. Cell Death and Disease, 2017, 8, e2753-e2753.	6.3	79
213	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro-Oncology, 2018, 20, 367-379.	1.2	79
214	How we treat patients with leptomeningeal metastases. ESMO Open, 2019, 4, e000507.	4.5	79
215	MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget, 2014, 5, 7651-7662.	1.8	79
216	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 2013, 15, 1017-1026.	1.2	78

#	Article	IF	Citations
217	Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. Brain, 2005, 128, 2200-2211.	7.6	77
218	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 2012, 123, 841-852.	7.7	77
219	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 2014, 16, 1630-1638.	1.2	77
220	Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. Neuro-Oncology, 2014, 16, viii14-viii19.	1.2	77
221	Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer, 2016, 122, 2206-2215.	4.1	77
222	The network of immunosuppressive pathways in glioblastoma. Biochemical Pharmacology, 2017, 130, 1-9.	4.4	76
223	Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Therapy, 2004, 11, 721-732.	4.6	75
224	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro-Oncology, 2021, 23, 881-893.	1.2	75
225	A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology, 2008, 10, 1019-1024.	1.2	74
226	2â€Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. International Journal of Cancer, 2012, 131, 766-768.	5.1	74
227	Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathologica, 2016, 131, 309-319.	7.7	74
228	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathologica, 2019, 138, 295-308.	7.7	74
229	Topoisomerase-I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and Î²-lapachone. , 1997, 73, 707-714.		73
230	Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Annals of Neurology, 1998, 43, 116-120.	5.3	73
231	BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. Journal of the Neurological Sciences, 1998, 155, 68-75.	0.6	73
232	NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. Clinical Cancer Research, 2018, 24, 882-895.	7.0	73
233	Pirfenidone inhibits TGF-Î² expression in malignant glioma cells. Biochemical and Biophysical Research Communications, 2007, 354, 542-547.	2.1	72
234	Synergistic antiglioma activity of radiotherapy and enzastaurin. Annals of Neurology, 2007, 61, 153-161.	5.3	72

#	Article	IF	Citations
235	Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. Journal of Controlled Release, 2019, 295, 130-139.	9.9	72
236	Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. Cancer, 2002, 95, 1113-1119.	4.1	71
237	Inhibition of Epidermal Growth Factor Receptor Signaling Protects Human Malignant Glioma Cells from Hypoxia-Induced Cell Death. Cancer Research, 2004, 64, 1575-1578.	0.9	71
238	Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathologica, 2011, 122, 353-365.	7.7	71
239	Bevacizumab does not increase the risk of remote relapse in malignant glioma. Annals of Neurology, 2011, 69, 586-592.	5.3	71
240	Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro-Oncology, 2018, 20, 279-288.	1.2	71
241	Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro-Oncology, 2014, 16, 584-588.	1.2	70
242	CD95 Ligand: Lethal Weapon Against Malignant Glioma?. Brain Pathology, 1998, 8, 285-293.	4.1	69
243	Immunocytokines are a promising immunotherapeutic approach against glioblastoma. Science Translational Medicine, 2020, 12, .	12.4	69
244	Dynamic ¹⁸<scp>Fâ€FET PET</scp> in suspected <scp>WHO</scp> grade II gliomas defines distinct biological subgroups with different clinical courses. International Journal of Cancer, 2015, 136, 2132-2145.	5.1	68
245	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research, 2022, 28, 594-602.	7.0	67
246	Differential regulation of TGF-Î²â€“induced, ALK-5â€“mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. Neuro-Oncology, 2015, 17, 254-265.	1.2	65
247	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. Neuro-Oncology, 2018, 20, 1616-1624.	1.2	65
248	Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?. Oncogene, 1998, 17, 1567-1575.	5.9	64
249	Individualized Targeted Therapy for Glioblastoma. Cancer Journal (Sudbury, Mass), 2012, 18, 40-44.	2.0	64
250	Predicting outcome of epilepsy after meningioma resection. Neuro-Oncology, 2016, 18, 1002-1010.	1.2	64
251	Lymphatic outflow of cerebrospinal fluid is reduced in glioma. Scientific Reports, 2019, 9, 14815.	3.3	64
252	SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro-Oncology, 2021, 23, 1835-1844.	1.2	64

#	Article	IF	Citations
253	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 27, 851-852.	4.1	63
254	Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro-Oncology, 2020, 22, 524-538.	1.2	63
255	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget, 2016, 7, 15018-15032.	1.8	62
256	How we treat glioblastoma. ESMO Open, 2019, 4, e000520.	4.5	62
257	Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro-Oncology, 2016, 18, 1242-1252.	1.2	61
258	Targeting apoptosis pathways in glioblastoma. Cancer Letters, 2013, 332, 335-345.	7.2	60
259	Pharmacotherapy of Epileptic Seizures in Glioma Patients: Who, When, Why and How Long?. Oncology Research and Treatment, 2005, 28, 391-396.	1.2	59
260	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro-Oncology, 2021, 23, 1100-1112.	1.2	59
261	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-Oncology, 2016, 18, 744-751.	1.2	58
262	CODEL: phase III study of RT, RTâ€‰+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology, 2021, 23, 457-467.	1.2	58
263	MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Oncotarget, 2016, 7, 12937-12950.	1.8	58
264	Radiochemotherapy of Malignant Glioma in Adults. Strahlentherapie Und Onkologie, 2003, 179, 219-232.	2.0	57
265	Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1815-1821.	2.5	57
266	Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochemical and Biophysical Research Communications, 2004, 321, 524-530.	2.1	56
267	Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. Journal of Neuroimmunology, 2007, 189, 50-58.	2.3	56
268	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-Oncology, 2018, 20, 400-410.	1.2	56
269	Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro-Oncology, 2019, 21, 1587-1594.	1.2	56
270	EANOâ€“EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncology, The, 2019, 20, e715-e728.	10.7	56

#	Article	IF	Citations
271	Modulation of cerebral endothelial cell function by TGF-Î² in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. Oncotarget, 2015, 6, 22480-22495.	1.8	56
272	Selective Potentiation of Drug Cytotoxicity by NSAID in Human Glioma Cells: The Role of COX-1 and MRP. Biochemical and Biophysical Research Communications, 1999, 259, 600-605.	2.1	55
273	Chemotherapyâ€induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. Journal of Neurochemistry, 2004, 91, 1067-1074.	3.9	54
274	Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochemical and Biophysical Research Communications, 2005, 328, 125-129.	2.1	54
275	NOAâ€05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Annals of Neurology, 2011, 70, 445-453.	5.3	54
276	Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology, 2017, 88, 1422-1430.	1.1	54
277	Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene, 2001, 20, 4757-4767.	5.9	53
278	FasL (CD95L/APO-1L) Resistance of Neurons Mediated by Phosphatidylinositol 3-Kinase-Akt/Protein Kinase B-Dependent Expression of Lifeguard/Neuronal Membrane Protein 35. Journal of Neuroscience, 2005, 25, 6765-6774.	3.6	53
279	Modulation of TGFâ€Î² activity by latent TGFâ€Î²â€binding protein 1 in human malignant glioma cells. International Journal of Cancer, 2009, 125, 530-540.	5.1	53
280	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncology, 2016, 18, 401-407.	1.2	53
281	Glioblastoma quo vadis : Will migration and invasiveness reemerge as therapeutic targets?. Cancer Treatment Reviews, 2018, 68, 145-154.	7.7	53
282	Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. Neurological Research, 1997, 19, 456-470.	1.3	52
283	Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Cell Death and Differentiation, 1998, 5, 894-900.	11.2	52
284	Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of Neuro-Oncology, 2014, 117, 141-145.	2.9	52
285	Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. Journal of Neuro-Oncology, 2017, 133, 419-427.	2.9	52
286	Management of low-grade glioma: a systematic review and meta-analysis. Neuro-Oncology Practice, 2019, 6, 249-258.	1.6	52
287	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. The Lancet Digital Health, 2021, 3, e784-e794.	12.3	52
288	Corticosteroid use in neuro-oncology: an update. Neuro-Oncology Practice, 2015, 2, 6-12.	1.6	51

#	Article	IF	Citations
289	Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. Journal of the National Cancer Institute, 2017, 109, 1-4.	6.3	51
290	Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide. International Journal of Radiation Oncology Biology Physics, 2010, 77, 670-676.	0.8	50
291	MiRâ€16â€5p is frequently downâ€regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy. Neuropathology and Applied Neurobiology, 2019, 45, 441-458.	3.2	50
292	Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell Immunity Independent of Indoleamine 2,3-Dioxygenase 1 (IDO1). Stem Cells and Development, 2010, 19, 657-668.	2.1	49
293	Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence. Current Neurology and Neuroscience Reports, 2011, 11, 305-312.	4.2	49
294	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncology, The, 2012, 13, e196-e204.	10.7	49
295	A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro-Oncology, 2014, 16, 382-391.	1.2	49
296	Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. Oncogene, 1999, 18, 5044-5053.	5.9	48
297	Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. European Journal of Pharmacology, 1999, 365, 301-308.	3.5	48
298	BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. Journal of Neuro-Oncology, 2002, 56, 43-49.	2.9	48
299	Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. Nature Communications, 2020, 11, 6434.	12.8	48
300	How Lymphotoxic Is Dose-Intensified Temozolomide? The Glioblastoma Experience. Journal of Clinical Oncology, 2005, 23, 4235-4236.	1.6	47
301	Immunological challenges for peptide-based immunotherapy in glioblastoma. Cancer Treatment Reviews, 2014, 40, 248-258.	7.7	47
302	Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. Journal of Neurochemistry, 2014, 131, 251-264.	3.9	47
303	Interferon-Î² Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells. Molecular Cancer Therapeutics, 2014, 13, 948-961.	4.1	47
304	Biological Role and Therapeutic Targeting of TGF-Î²3 in Glioblastoma. Molecular Cancer Therapeutics, 2017, 16, 1177-1186.	4.1	47
305	Primary central nervous system lymphoma 1991-1997. Cancer, 2001, 91, 130-135.	4.1	46
306	Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro-Oncology, 2015, 17, 1016-1021.	1.2	46

#	Article	IF	Citations
307	EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2001-2001.	1.6	46
308	Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Medical Weekly, 2011, 141, w13210.	1.6	46
309	Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochirurgica, 2012, 154, 229-235.	1.7	45
310	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	7.7	45
311	A tissue-based draft map of the murine MHC class I immunopeptidome. Scientific Data, 2018, 5, 180157.	5.3	45
312	Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. Glia, 2011, 59, 1200-1204.	4.9	44
313	Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain, 2014, 137, 433-448.	7.6	44
314	Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. Neuro-Oncology, 2017, 19, 1338-1349.	1.2	44
315	ACNU-based chemotherapy for recurrent glioma in the temozolomide era. Journal of Neuro-Oncology, 2009, 92, 45-48.	2.9	43
316	ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi17-vi18.	1.2	43
317	Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain, 2009, 132, 1509-1522.	7.6	42
318	APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-Oncology, 2011, 13, 155-164.	1.2	42
319	Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. International Journal of Cancer, 2020, 146, 803-809.	5.1	42
320	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro-Oncology, 2020, 22, 1162-1172.	1.2	42
321	Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. Lancet Oncology, The, 2020, 21, e97-e103.	10.7	42
322	Effect of the integrin inhibitor cilengitide on TGF-beta signaling.. Journal of Clinical Oncology, 2012, 30, 2055-2055.	1.6	42
323	Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. Journal of Neuro-Oncology, 1998, 39, 19-32.	2.9	41
324	Pâ€Glycoprotein and Multidrug Resistanceâ€associated Protein Mediate Specific Patterns of Multidrug Resistance in Malignant Glioma Cell Lines, but not in Primary Glioma Cells. Brain Pathology, 2003, 13, 482-494.	4.1	41

#	Article	IF	Citations
325	Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Review of Anticancer Therapy, 2013, 13, 1319-1325.	2.4	41
326	Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. Multiple Sclerosis Journal, 2016, 22, 1463-1475.	3.0	41
327	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology, 2018, 20, 897-906.	1.2	41
328	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. Journal of Clinical Oncology, 2016, 34, TPS2079-TPS2079.	1.6	41
329	Interferon-Î± enhances CD95L-induced apoptosis of human malignant glioma cells. Journal of Neuroimmunology, 1998, 87, 121-129.	2.3	40
330	Death receptor-mediated apoptosis in human malignant glioma cells: Modulation by the CD40/CD40L system. Journal of Neuroimmunology, 2005, 162, 28-42.	2.3	40
331	Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells. NeuroSignals, 2017, 25, 26-38.	0.9	40
332	Control of glioma cell migration and invasiveness by GDF-15. Oncotarget, 2016, 7, 7732-7746.	1.8	40
333	New aspects of immunotherapy of leptomeningeal metastasis. Journal of Neuro-Oncology, 1998, 38, 233-239.	2.9	39
334	The Role of Integrins in Glioma Biology and Anti-Glioma Therapies. Current Pharmaceutical Design, 2011, 17, 2402-2410.	1.9	39
335	HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. Journal of Neuroimmunology, 2012, 250, 27-34.	2.3	39
336	Efficacy of Surgery and Further Treatment of Progressive Glioblastoma. World Neurosurgery, 2015, 84, 301-307.	1.3	39
337	Iterative analysis of cerebrovascular reactivity dynamic response by temporal decomposition. Brain and Behavior, 2017, 7, e00705.	2.2	39
338	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology, 2022, 24, 1613-1646.	1.2	39
339	Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochromeâ€‰c release. Oncogene, 2000, 19, 2338-2345.	5.9	38
340	Temozolomide: a milestone in the pharmacotherapy of brain tumors. Future Oncology, 2005, 1, 747-754.	2.4	38
341	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta OncolÃ³gica, 2011, 50, 630-635.	1.8	38
342	Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1007-1015.	1.2	38

#	Article	IF	Citations
343	Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. EMBO Molecular Medicine, 2019, 11, .	6.9	38
344	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro-Oncology, 2020, 22, 1568-1579.	1.2	38
345	Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.. Journal of Clinical Oncology, 2019, 37, 2000-2000.	1.6	38
346	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology, 2022, 24, 855-871.	1.2	38
347	BCL-2-induced glioma cell invasiveness depends on furin-like proteases. Journal of Neurochemistry, 2004, 91, 1275-1283.	3.9	37
348	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	5.2	37
349	Modulation of MDR/MRP by wild-type and mutant p53. Journal of Clinical Investigation, 2001, 107, 643-645.	8.2	37
350	CD95-Dependent T-Cell Killing by Glioma Cells Expressing CD95 Ligand: More on Tumor Immune Escape, the CD95 Counterattack, and the Immune Privilege of the Brain. Cellular Physiology and Biochemistry, 1997, 7, 282-288.	1.6	36
351	CD95â€mediated Apoptosis of Human Glioma Cells: Modulation by Epidermal Growth Factor Receptor Activity. Brain Pathology, 2002, 12, 12-20.	4.1	36
352	Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunityin vivo. International Journal of Cancer, 2006, 118, 1728-1735.	5.1	36
353	Malignant optic glioma â€“ the spectrum of disease in a case series. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1187-1194.	1.9	36
354	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathologica, 2018, 135, 923-938.	7.7	36
355	Barriers to accrual and enrollment in brain tumor trials. Neuro-Oncology, 2019, 21, 1100-1117.	1.2	36
356	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. Neuro-Oncology, 2019, 21, 1447-1457.	1.2	35
357	End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. Neuro-Oncology, 2013, 15, 1251-1256.	1.2	34
358	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. European Journal of Cancer, 2017, 87, 189-198.	2.8	34
359	Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression. ACS Central Science, 2021, 7, 868-881.	11.3	34
360	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	1.2	34

#	Article	IF	Citations
361	Neurological complications of cancer immunotherapy. Cancer Treatment Reviews, 2021, 97, 102189.	7.7	34
362	Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. FEBS Letters, 1997, 409, 17-23.	2.8	33
363	Adenoviral Natural Born Killer Gene Therapy for Malignant Glioma. Human Gene Therapy, 2003, 14, 1235-1246.	2.7	33
364	Therapeutic Targeting of TGFÎ² Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas. Clinical Cancer Research, 2019, 25, 7189-7201.	7.0	33
365	Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. Cancer Letters, 2020, 480, 24-28.	7.2	33
366	T Cell Apoptosis Induced by Interleukin-2 Deprivation or Transforming Growth Factor-Î²2: Modulation by the Phosphatase Inhibitors Okadaic Acid and Calyculin A. Experimental Cell Research, 1995, 221, 395-403.	2.6	32
367	TGF-Î²-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. European Journal of Immunology, 1999, 29, 1032-1040.	2.9	32
368	Long-term control and partial remission after initial pseudoprogression of glioblastoma by antiâ€“PD-1 treatment with nivolumab. Neuro-Oncology, 2017, 19, now265.	1.2	32
369	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. Current Treatment Options in Oncology, 2016, 17, 51.	3.0	32
370	Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. Neurology, 2017, 88, 832-841.	1.1	32
371	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. Lancet Oncology, The, 2018, 19, e173-e180.	10.7	32
372	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	7.7	32
373	Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica?. Pain, 2010, 149, 470-475.	4.2	31
374	Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro-Oncology, 2013, 15, 971-971.	1.2	31
375	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321.		31
376	Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. European Journal of Cancer, 2015, 51, 382-390.	2.8	31
377	Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-Î² dexamethasone, and p53 gene transfer. Oncogene, 1998, 17, 2323-2332.	5.9	30
378	Bagâ€1 and Bclâ€2 Gene Transfer in Malignant Glioma: Modulation of Cell Cycle Regulation and Apoptosis. Brain Pathology, 2000, 10, 223-234.	4.1	30

#	Article	IF	Citations
379	Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. Cancer, 2001, 91, 423-427.	4.1	30
380	Expression and putative functions of GDF-15, a member of the TGF-Î² superfamily, in human glioma and glioblastoma cell lines. Cancer Letters, 2008, 270, 30-39.	7.2	30
381	Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. Journal of Neurosurgery, 2010, 113, 280-285.	1.6	30
382	Immunological effects of chemotherapy and radiotherapy against brain tumors. Expert Review of Anticancer Therapy, 2016, 16, 1087-1094.	2.4	30
383	Negative control of the HGF/c-MET pathway by TGF-Î²: a new look at the regulation of stemness in glioblastoma. Cell Death and Disease, 2017, 8, 3210.	6.3	30
384	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nature Medicine, 2022, 28, 752-765.	30.7	30
385	Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. Acta Neuropathologica, 2001, 101, 217-224.	7.7	29
386	Interleukin-33 in human gliomas: Expression and prognostic significance. Oncology Letters, 2016, 12, 445-452.	1.8	29
387	Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. Journal of Neuro-Oncology, 2016, 129, 165-171.	2.9	28
388	Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?. Journal of Neuro-Oncology, 2018, 138, 163-171.	2.9	28
389	Copy number profiling across glioblastoma populations has implications for clinical trial design. Neuro-Oncology, 2018, 20, 1368-1373.	1.2	28
390	Proteasome inhibition for the treatment of glioblastoma. Expert Opinion on Investigational Drugs, 2020, 29, 1133-1141.	4.1	28
391	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O⁶-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. Journal of Clinical Oncology, 2013, 31, LBA2009-LBA2009.	1.6	28
392	Direct contact with perivascular tumor cells enhances integrin Î±vÎ²3 signaling and migration of endothelial cells. Oncotarget, 2016, 7, 43852-43867.	1.8	28
393	Potentiation of Treosulfan Toxicity by the Glutathione-Depleting Agent Buthionine Sulfoximine in Human Malignant Glioma Cells. Biochemical Pharmacology, 1998, 55, 349-359.	4.4	27
394	p53 Enhances BAK and CD95 Expression in Human Malignant Glioma Cells but Does Not Enhance CD95L-Induced Apoptosis. Cellular Physiology and Biochemistry, 1999, 9, 29-37.	1.6	27
395	Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study. Journal of Neuro-Oncology, 2002, 59, 151-155.	2.9	27
396	Involvement of protein kinase CÎ´ and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). Biochemical Pharmacology, 2003, 66, 1263-1270.	4.4	27

#	Article	IF	Citations
397	Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas. European Neurology, 2013, 69, 95-101.	1.4	27
398	Limited role for transforming growth factorâ€“Î² pathway activation-mediated escape from VEGF inhibition in murine glioma models. Neuro-Oncology, 2016, 18, 1610-1621.	1.2	27
399	TGF-Î² induces oncofetal fibronectin, which in turn modulates TGF-Î² superfamily signaling in endothelial cells. Journal of Cell Science, 2018, 131, .	2.0	27
400	Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. Blood, 2018, 132, 2744-2753.	1.4	27
401	Profound, durable and MGMTâ€independent sensitivity of glioblastoma cells to cyclinâ€dependent kinase inhibition. International Journal of Cancer, 2019, 145, 242-253.	5.1	27
402	Risk factors for the development of epilepsy in patients with brain metastases. Neuro-Oncology, 2020, 22, 718-728.	1.2	27
403	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535.	7.0	27
404	Caspase-Dependent Chemotherapy-Induced Death of Glioma Cells Requires Mitochondrial Cytochrome c Release. Biochemical and Biophysical Research Communications, 2001, 281, 322-327.	2.1	26
405	Enzastaurinâ€induced apoptosis in glioma cells is caspaseâ€dependent and inhibited by BCLâ€X_L. Journal of Neurochemistry, 2008, 106, 2436-2448.	3.9	26
406	Shaping the glioma immune microenvironment through tryptophan metabolism. CNS Oncology, 2012, 1, 99-106.	3.0	26
407	Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastasesâ€”development and validation of the LabBM score. Neuro-Oncology, 2017, 19, now290.	1.2	26
408	Accumulation of Mutant p53V143A Modulates the Growth, Clonogenicity, and Radiochemosensitivity of Malignant Glioma Cells Independent of Endogenous p53 Status. Experimental Cell Research, 1999, 253, 432-439.	2.6	25
409	Will integrin inhibitors have proangiogenic effects in the clinic?. Nature Medicine, 2009, 15, 726-726.	30.7	25
410	Geriatric neuro-oncology. Current Opinion in Neurology, 2011, 24, 599-604.	3.6	25
411	Immunotherapy for glioblastoma. Current Opinion in Neurology, 2015, 28, 639-646.	3.6	25
412	Diffuse gliomas exhibit whole brain impaired cerebrovascular reactivity. Magnetic Resonance Imaging, 2018, 45, 78-83.	1.8	25
413	Treatment Monitoring of Immunotherapy and Targeted Therapy Using ¹⁸F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. Journal of Nuclear Medicine, 2021, 62, 464-470.	5.0	25
414	Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. Journal of Clinical Oncology, 2015, 33, 2015-2015.	1.6	25

#	Article	IF	Citations
415	Management of neoplastic meningitis. Chinese Clinical Oncology, 2015, 4, 26.	1.2	25
416	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071â€“22072 and CORE Trials. Clinical Cancer Research, 2022, 28, 129-136.	7.0	25
417	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro-Oncology, 2022, 24, 755-767.	1.2	25
418	Tumor cell dissemination triggers an intrathecal immune response in neoplastic meningitis. Cancer, 1992, 69, 1475-1480.	4.1	24
419	Regeneration and Tolerance Factor: A Novel Mediator of Glioblastoma-Associated Immunosuppression. Cancer Research, 2006, 66, 3852-3858.	0.9	24
420	Mechanisms of Resistance of Human Glioma Cells to Apo2 Ligand/TNF-Related Apoptosis-Inducing Ligand. Cellular Physiology and Biochemistry, 2007, 20, 023-034.	1.6	24
421	Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?. Expert Opinion on Investigational Drugs, 2012, 21, 605-617.	4.1	24
422	Pharmacotherapies for the treatment of glioblastoma â€“ current evidence and perspectives. Expert Opinion on Pharmacotherapy, 2016, 17, 1259-1270.	1.8	24
423	Transcriptional control of O⁶â€methylguanine <scp>DNA</scp> methyltransferase expression and temozolomide resistance in glioblastoma. Journal of Neurochemistry, 2018, 144, 780-790.	3.9	24
424	Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. JCI Insight, 2019, 4, .	5.0	24
425	Inhibition of experimental rat glioma growth by decorin gene transfer is associated with decreased microglial infiltration. Journal of Neuroimmunology, 1999, 99, 13-18.	2.3	23
426	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. Future Oncology, 2010, 6, 1407-1414.	2.4	23
427	3-Nitropropionic Acid-Induced Ischemia Tolerance in the Rat Brain is Mediated by Reduced Metabolic Activity and Cerebral Blood Flow. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1522-1530.	4.3	23
428	Computer-assisted quantification of motile and invasive capabilities of cancer cells. Scientific Reports, 2015, 5, 15338.	3.3	23
429	Chemotherapy for intracranial ependymoma in adults. BMC Cancer, 2016, 16, 287.	2.6	23
430	Predisposing and precipitating factors for delirium in neurology: a prospective cohort study of 1487 patients. Journal of Neurology, 2019, 266, 3065-3075.	3.6	23
431	Predisposing and precipitating risk factors for delirium in palliative care patients. Palliative and Supportive Care, 2020, 18, 437-446.	1.0	23
432	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology, 2020, 22, 601-612.	1.2	23

#	Article	IF	Citations
433	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. European Journal of Cancer, 2019, 116, 190-198.	2.8	22
434	The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. Cell Death and Disease, 2021, 12, 885.	6.3	22
435	Apoptosis in gliomas and its role in their current and future treatment. Frontiers in Bioscience - Landmark, 2002, 7, e339-353.	3.0	21
436	Anticoagulation for radiation-induced neurotoxicity revisited. Journal of Neuro-Oncology, 2008, 90, 357-362.	2.9	21
437	VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. Brain, 2008, 131, 2579-2595.	7.6	21
438	Ceramide metabolism determines glioma cell resistance to chemotherapy. Journal of Cellular Physiology, 2009, 221, 688-695.	4.1	21
439	Pathogenesis and management of primary CNS lymphoma. Expert Review of Anticancer Therapy, 2012, 12, 623-633.	2.4	21
440	Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma. Current Neurology and Neuroscience Reports, 2012, 12, 302-307.	4.2	21
441	Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. Journal of Neuro-Oncology, 2014, 118, 321-328.	2.9	21
442	Altered intraoperative cerebrovascular reactivity in brain areas of high-grade glioma recurrence. Magnetic Resonance Imaging, 2016, 34, 803-808.	1.8	21
443	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget, 2016, 7, 82028-82045.	1.8	21
444	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-Î³ (IFN-Î³). British Journal of Pharmacology, 2001, 134, 1279-1284.	5.4	20
445	Improving outcome in newly diagnosed malignant glioma. Nature Reviews Neurology, 2014, 10, 68-70.	10.1	20
446	Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. Journal of Neurochemistry, 2018, 147, 99-109.	3.9	20
447	Defining EGFR amplification status for clinical trial inclusion. Neuro-Oncology, 2019, 21, 1263-1272.	1.2	20
448	CHD7 promotes glioblastoma cell motility and invasiveness through transcriptional modulation of an invasion signature. Scientific Reports, 2019, 9, 3952.	3.3	20
449	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. ESMO Open, 2020, 5, e000763.	4.5	20
450	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. Journal of Clinical Oncology, 2016, 34, LBA2000-LBA2000.	1.6	20

#	Article	IF	Citations
451	SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo. Clinical Cancer Research, 2009, 15, 6609-6618.	7.0	19
452	Neuro-oncology, a decade of temozolomide and beyond. Expert Review of Anticancer Therapy, 2010, 10, 1675-1677.	2.4	19
453	Novel <scp>TIE</scp>â€2 inhibitor <scp>BAY</scp>â€826 displays inÂvivo efficacy in experimental syngeneic murine glioma models. Journal of Neurochemistry, 2017, 140, 170-182.	3.9	19
454	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine, 2020, 9, 8373-8385.	2.8	19
455	An engineered 4-1BBL fusion protein with â€œactivity on demandâ€. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31780-31788.	7.1	19
456	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. Radiology, 2020, 297, 164-175.	7.3	19
457	Determining medical decision-making capacity in brain tumor patients: why and how?. Neuro-Oncology Practice, 2020, 7, 599-612.	1.6	19
458	Subacute cerebellar ataxia following respiratory symptoms of COVID-19: a case report. BMC Infectious Diseases, 2021, 21, 298.	2.9	19
459	A prospective trial of mechanical physiotherapy for lumbar disk prolapse. Journal of Neurology, 2003, 250, 746-749.	3.6	18
460	Supraagonistic, bispecific singleâ€chain antibody purified from the serum of cloned, transgenic cows induces Tâ€cellâ€mediated killing of glioblastoma cells in vitro and in vivo. International Journal of Cancer, 2005, 117, 1060-1064.	5.1	18
461	Glioma Cell Death Induced by Irradiation or Alkylating Agent Chemotherapy Is Independent of the Intrinsic Ceramide Pathway. PLoS ONE, 2013, 8, e63527.	2.5	18
462	Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wildâ€type glioblastoma. Genes Chromosomes and Cancer, 2014, 53, 589-605.	2.8	18
463	Anticonvulsive effect of anterior thalamic deep brain stimulation in super-refractory status epilepticus crucially depends on active stimulation zoneâ€”A single case observation. Seizure: the Journal of the British Epilepsy Association, 2019, 71, 286-288.	2.0	18
464	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. Neuro-Oncology, 2019, 21, vi137-vi137.	1.2	18
465	Development of a gene expressionâ€“based prognostic signature for IDH wild-type glioblastoma. Neuro-Oncology, 2020, 22, 1742-1756.	1.2	18
466	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2021, 39, 2004-2004.	1.6	18
467	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	7.0	18
468	Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. Oncotarget, 2016, 7, 81995-82012.	1.8	18

#	Article	IF	Citations
469	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. Neuro-Oncology, 2022, 24, 1726-1735.	1.2	18
470	Maturation-dependent Modulation of Apoptosis in Cultured Cerebellar Granule Neurons by Cytokines and Neurotrophins. European Journal of Neuroscience, 1996, 8, 1994-2005.	2.6	17
471	Diva/Boo is a negative regulator of cell death in human glioma cells. FEBS Letters, 2001, 505, 23-26.	2.8	17
472	Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.7	17
473	Treatment of Primary CNS Lymphoma. Current Treatment Options in Neurology, 2014, 16, 277.	1.8	17
474	Glioblastoma in the elderly: making sense of the evidence. Neuro-Oncology Practice, 2016, 3, 77-86.	1.6	17
475	Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. European Journal of Cancer, 2018, 96, 64-72.	2.8	17
476	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma. Neurology, 2019, 93, e1799-e1806.	1.1	17
477	Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation. Molecular Cancer Therapeutics, 2020, 19, 1328-1339.	4.1	17
478	Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies. Current Treatment Options in Oncology, 2013, 14, 505-513.	3.0	16
479	Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. Acta Neuropathologica, 2013, 126, 21-37.	7.7	16
480	Letter to the Editor: â€œThe role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guidelineâ€•[J Neurooncol 2014; 118:435â€“460]. Journal of Neuro-Oncology, 2014, 120, 665-666.	2.9	16
481	Boswellic acid activity against glioblastoma stem-like cells. Oncology Letters, 2016, 11, 4187-4192.	1.8	16
482	Pseudoprogression: fact or wishful thinking in neuro-oncology?. Lancet Oncology, The, 2018, 19, 1561-1563.	10.7	16
483	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro-Oncology, 2019, 21, 234-241.	1.2	16
484	How we treat patients with brain tumour during the COVID-19 pandemic. ESMO Open, 2019, 4, e000789.	4.5	16
485	MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clinical Cancer Research, 2021, 27, 179-188.	7.0	16
486	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. European Journal of Cancer, 2021, 156, 93-108.	2.8	16

#	Article	IF	Citations
487	CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548. Neuro-Oncology, 2021, 23, vi55-vi56.	1.2	16
488	Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. International Journal of Oncology, 2008, 33, 759-65.	3.3	16
489	Regulation of pulmonary Pseudomonas aeruginosa infection by the transcriptional repressor Gfi1. Cellular Microbiology, 2006, 8, 1096-1105.	2.1	15
490	Does cilengitide deserve another chance?â€“Authors' reply. Lancet Oncology, The, 2014, 15, e585-e586.	10.7	15
491	How Stemlike Are Sphere Cultures From Long-term Cancer Cell Lines? Lessons From Mouse Glioma Models. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1062-1077.	1.7	15
492	Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF-Î² and Furin in Glioma-Initiating Cells. Journal of Immunology, 2017, 198, 4569-4574.	0.8	15
493	Contraceptive drugs mitigate experimental stroke-induced brain injury. Cardiovascular Research, 2019, 115, 637-646.	3.8	15
494	FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. Acta Neuropathologica, 2020, 139, 175-192.	7.7	15
495	Does Neuronal Activity Promote Glioma Progression?. Trends in Cancer, 2020, 6, 1-3.	7.4	15
496	Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?. Current Opinion in Neurology, 2020, 33, 701-706.	3.6	15
497	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. Frontiers in Oncology, 2021, 11, 636672.	2.8	15
498	Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. Cancers, 2021, 13, 3073.	3.7	15
499	RetroviralBAX gene transfer fails to sensitize malignant glioma cells to CD95L-induced apoptosis and cancer chemotherapy. , 1998, 77, 645-648.		14
500	Cellular stimulation via CD95 involves activation of phospho-inositide-3-kinase. Pflugers Archiv European Journal of Physiology, 1998, 435, 546.	2.8	14
501	Defective p53 antiangiogenic signaling in glioblastoma. Neuro-Oncology, 2010, 12, 894-907.	1.2	14
502	Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients. Swiss Medical Weekly, 2012, 142, w13615.	1.6	14
503	Immunology of brain tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 45-51.	1.8	14
504	Genetic variants of homocysteine metabolism and multiple sclerosis: A caseâ€“control study. Neuroscience Letters, 2014, 562, 75-78.	2.1	14

#	Article	IF	Citations
505	Immunotherapy of Brain Cancer. Oncology Research and Treatment, 2016, 39, 326-334.	1.2	14
506	Immunotherapy for glioblastoma: quo vadis?. Nature Reviews Clinical Oncology, 2019, 16, 405-406.	27.6	14
507	ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE. Neuro-Oncology, 2019, 21, vi21-vi22.	1.2	14
508	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 659-670.	2.5	14
509	Survival of brain tumour patients with epilepsy. Brain, 2021, 144, 3322-3327.	7.6	14
510	Investigational PET tracers in neuro-oncologyâ€"Whatâ€™s on the horizon? A report of the PET/RANO group. Neuro-Oncology, 2022, 24, 1815-1826.	1.2	14
511	Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. Journal of Neuro-Oncology, 1998, 37, 191-198.	2.9	13
512	MIP-1Â Antagonizes the Effect of a GM-CSF-Enhanced Subcutaneous Vaccine in a Mouse Glioma Model. Journal of Neuro-Oncology, 2004, 66, 147-154.	2.9	13
513	Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma. Chemotherapy, 2014, 60, 375-378.	1.6	13
514	Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro-Oncology, 2014, 16, 765-767.	1.2	13
515	ATPS-73BIOLOGICAL ACTIVITY OF TUMOR-TREATING FIELDS (TTFIELDS) IN GLIOMA MODELS IN A PRECLINICAL SETTING. Neuro-Oncology, 2015, 17, v34.3-v34.	1.2	13
516	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e132-e139.	3.8	13
517	Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 422-429.	2.5	13
518	Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis. European Journal of Cancer, 2020, 124, 194-203.	2.8	13
519	Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-Î² and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab058.	0.7	13
520	PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. Journal of Neuro-Oncology, 2021, 153, 283-291.	2.9	13
521	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. Journal of Clinical Oncology, 2019, 37, 2007-2007.	1.6	13
522	Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid. PLoS ONE, 2014, 9, e94921.	2.5	13

#	Article	IF	Citations
523	Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours. ESMO Open, 2020, 5, e001034.	4.5	13
524	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. Neuro-Oncology, 2022, 24, 1533-1545.	1.2	13
525	CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression. FEBS Letters, 1998, 432, 155-157.	2.8	12
526	Assessing the MGMT status in glioblastoma: one step forward, two steps back?. Neuro-Oncology, 2013, 15, 253-254.	1.2	12
527	Management of Elderly Patients with Glioblastoma. Current Neurology and Neuroscience Reports, 2017, 17, 35.	4.2	12
528	Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. Acta Neuropathologica, 2017, 134, 905-922.	7.7	12
529	Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. International Journal of Pharmaceutics, 2018, 536, 388-396.	5.2	12
530	Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. Journal of Neuro-Oncology, 2020, 148, 117-130.	2.9	12
531	End-of-life care for glioma patients; the caregiversâ€™ perspective. Journal of Neuro-Oncology, 2020, 147, 663-669.	2.9	12
532	A clinically compatible drugâ€screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. EMBO Molecular Medicine, 2022, 14, e14552.	6.9	12
533	CD95 ligand-induced apoptosis of human medulloblastoma cells. Cancer Letters, 1998, 128, 121-126.	7.2	11
534	Classification and management of anaplastic gliomas. Current Opinion in Neurology, 2009, 22, 650-656.	3.6	11
535	Trabedersen to target transforming growth factor-Â: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). Neuro-Oncology, 2011, 13, 559-560.	1.2	11
536	Differential Expression of the Tumor Suppressor A-Kinase Anchor Protein 12 in Human Diffuse and Pilocytic Astrocytomas Is Regulated by Promoter Methylation. Journal of Neuropathology and Experimental Neurology, 2013, 72, 933-941.	1.7	11
537	Interferon-Î² Modulates the Innate Immune Response against Glioblastoma Initiating Cells. PLoS ONE, 2015, 10, e0139603.	2.5	11
538	Glioblastoma. , 2017, , 265-288.		11
539	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. Acta Neuropathologica, 2018, 136, 975-978.	7.7	11
540	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. European Journal of Cancer, 2018, 101, 95-104.	2.8	11

#	Article	IF	Citations
541	Venous thromboembolic events in patients with brain metastases: the PICOS score. European Journal of Cancer, 2020, 134, 75-85.	2.8	11
542	Socioeconomic burden and quality of life in meningioma patients. Quality of Life Research, 2020, 29, 1801-1808.	3.1	11
543	Anatomical phenotyping and staging of brain tumours. Brain, 2022, 145, 1162-1176.	7.6	11
544	Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network.. Journal of Clinical Oncology, 2014, 32, 2014-2014.	1.6	11
545	Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5-a]pyrimidine-Based Macrocycles. Journal of Medicinal Chemistry, 2022, 65, 7799-7817.	6.4	11
546	Treosulfan chemotherapy for recurrent malignant glioma. Journal of Neuro-Oncology, 2000, 49, 231-234.	2.9	10
547	Mechanisms of apoptosis in central nervous system tumors: Application to theory. Current Neurology and Neuroscience Reports, 2002, 2, 246-253.	4.2	10
548	Angiogenesis in glioblastoma: just another moving target?. Brain, 2010, 133, 955-956.	7.6	10
549	Glioma tropism of lentivirally transduced hematopoietic progenitor cells. International Journal of Oncology, 2010, 36, 1409-17.	3.3	10
550	Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). Journal of Neuro-Oncology, 2011, 104, 801-809.	2.9	10
551	The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma. Neuro-Oncology, 2014, 16, 1035-1036.	1.2	10
552	LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX â€“M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410. Neuro-Oncology, 2017, 19, vi316-vi316.	1.2	10
553	Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients. Journal of Neuro-Oncology, 2018, 140, 659-667.	2.9	10
554	Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumorsin vivo. MAbs, 2020, 12, 1836713.	5.2	10
555	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. European Journal of Cancer, 2020, 135, 150-158.	2.8	10
556	Telomerase reverse transcriptase promoter mutationâ€“ and O6-methylguanine DNA methyltransferase promoter methylationâ€“mediated sensitivity to temozolomide in isocitrate dehydrogenaseâ€“wild-type glioblastoma: is there a link?. European Journal of Cancer, 2021, 147, 84-94.	2.8	10
557	Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. European Journal of Cancer, 2021, 147, 1-12.	2.8	10
558	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux â€“M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. Journal of Clinical Oncology, 2018, 36, 2023-2023.	1.6	10

#	Article	IF	Citations
559	Synergy of CD95 ligand and teniposide: No role of cleavable complex formation and enhanced CD95 expression. European Journal of Pharmacology, 1998, 341, 323-328.	3.5	9
560	Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography. Neuro-Oncology, 2012, 14, 471-481.	1.2	9
561	Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?. Neuro-Oncology, 2013, 15, 809-810.	1.2	9
562	Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. Acta OncolÃ³gica, 2014, 53, 1436-1440.	1.8	9
563	The management of lomustine overdose in malignant glioma patients. Neuro-Oncology Practice, 2014, 1, 178-183.	1.6	9
564	The legend of cytomegalovirus and glioblastoma lives on. Neuro-Oncology, 2014, 16, 166-166.	1.2	9
565	Where does O⁶â€methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?. Cancer, 2018, 124, 1316-1318.	4.1	9
566	Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9. Neuro-Oncology, 2019, 21, 1607-1609.	1.2	9
567	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. Neurology, 2019, 92, e2754-e2763.	1.1	9
568	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology, 2020, 22, 1667-1676.	1.2	9
569	A vasculature-centric approach to developing novel treatment options for glioblastoma. Expert Opinion on Therapeutic Targets, 2021, 25, 87-100.	3.4	9
570	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. Neuro-Oncology Practice, 2021, 8, 417-425.	1.6	9
571	Cancer is associated with inferior outcome in patients with ischemic stroke. Journal of Neurology, 2021, 268, 4190-4202.	3.6	9
572	Economic Impact of Poststroke Delirium and Associated Risk Factors. Stroke, 2021, 52, 3325-3334.	2.0	9
573	Postranslationally Modified Proteins in the Central Nervous System (CNS) Are the Dominant Antigenic Target/Stimulus of the B-Cell Receptor (BCR) in Primary CNS Lymphomas (PCNSL) Providing Strong Evidence for the Role of Chronic Autoantigenic Stimulation As an Early Step in the Pathogenesis of Aggressive B-Cell Lymphomas. Blood, 2014, 124, 142-142.	1.4	9
574	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. Journal of Clinical Oncology, 2015, 33, 2001-2001.	1.6	9
575	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology, 2022, 24, 1219-1229.	1.2	9
576	Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma?. Neuro-Oncology, 2011, 13, 365-366.	1.2	8

#	Article	IF	Citations
577	Management of diffusely infiltrating glioma in the elderly. Current Opinion in Oncology, 2015, 27, 502-509.	2.4	8
578	Complementary and alternative medicine use in glioma patients in France. Journal of Neuro-Oncology, 2019, 145, 487-499.	2.9	8
579	Complementary and alternative medicine use by glioma patients in Switzerland. Neuro-Oncology Practice, 2019, 6, 237-244.	1.6	8
580	Crossed Cerebellar Diaschisis in Patients with Diffuse Glioma Is Associated with Impaired Supratentorial Cerebrovascular Reactivity and Worse Clinical Outcome. Cerebellum, 2020, 19, 824-832.	2.5	8
581	Development of Randomized Trials in Adults with Medulloblastomaâ€"The Example of EORTC 1634-BTG/NOA-23. Cancers, 2021, 13, 3451.	3.7	8
582	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. Journal of Clinical Oncology, 2016, 34, LBA2000-LBA2000.	1.6	8
583	Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. Oncotarget, 2017, 8, 87124-87135.	1.8	8
584	Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFRâ€"A Potential Therapeutic Target. International Journal of Molecular Sciences, 2021, 22, 10954.	4.1	8
585	Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions. Neuro-Oncology, 2023, 25, 290-302.	1.2	8
586	Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?. Journal of Neuro-Oncology, 1998, 40, 233-235.	2.9	7
587	Characterization of Daunorubicin-Induced Apoptosis in Retinal Pigment Epithelial Cells: Modulation by CD95L. , 2003, 44, 2851.		7
588	Malignant astrocytoma in elderly patients. Current Opinion in Neurology, 2013, 26, 693-700.	3.6	7
589	Reciprocal modulation of AÃŽÂ²42 aggregation by copper and homocysteine. Frontiers in Aging Neuroscience, 2014, 6, 237.	3.4	7
590	Neurologyâ€"the next 10 years. Nature Reviews Neurology, 2015, 11, 658-664.	10.1	7
591	Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. Journal of Neuro-Oncology, 2019, 145, 339-347.	2.9	7
592	Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. Journal of Neurochemistry, 2020, 153, 510-524.	3.9	7
593	The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis. Neuro-Oncology, 2022, 24, 429-441.	1.2	7
594	Endoglin and TGF-Î² signaling in glioblastoma. Cell and Tissue Research, 2021, 384, 613-624.	2.9	7

#	Article	IF	Citations
595	Primary Tumors of the Central and Peripheral Nervous System. , 2003, , 827-863.		7
596	Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. Neuro-Oncology, 2022, 24, 2159-2169.	1.2	7
597	Venous thromboembolic events in glioblastoma patients: An epidemiological study. European Journal of Neurology, 2022, 29, 2386-2397.	3.3	7
598	Comprehensive summary and retrospective evaluation of prognostic scores for patients with newly diagnosed brain metastases treated with upfront radiosurgery in a modern patient collective. Radiotherapy and Oncology, 2022, 172, 23-31.	0.6	7
599	Development of â€˜Core Outcome Setsâ€™ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings. BMJ Open, 2022, 12, e057384.	1.9	7
600	Prognostic validation and refinement of a classification system for extent of resection in glioblastoma: A report of the RANO resect group.. Journal of Clinical Oncology, 2022, 40, 2003-2003.	1.6	7
601	Genetic Regulation and Therapeutic Modulation of Apoptosis in Human Malignant Glioma. Cellular Physiology and Biochemistry, 1996, 6, 376-380.	1.6	6
602	p53 Accumulation Promotes Dephosphorylation and Proteolytic Cleavage of Retinoblastoma Protein in Human Malignant Glioma Cells. Cellular Physiology and Biochemistry, 1997, 7, 304-311.	1.6	6
603	Role of TGF-? in oncogenesis. Microscopy Research and Technique, 2001, 52, 353-353.	2.2	6
604	Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death. Journal of Neurochemistry, 2005, 92, 1340-1349.	3.9	6
605	Approval of new drugs for glioblastoma. Current Opinion in Neurology, 2009, 22, 617-618.	3.6	6
606	Temozolomide and MGMT forever?. Neuro-Oncology, 2010, 12, 219-220.	1.2	6
607	Whole-brain radiotherapy in primary CNS lymphoma â€“ Authors' reply. Lancet Oncology, The, 2011, 12, 119-120.	10.7	6
608	Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients. Pharmacoepidemiology and Drug Safety, 2012, 21, 872-880.	1.9	6
609	136â€ƒComplete Resection of Contrast-Enhancing Tumor Volume is Associated With Improved Survival in Recurrent Glioblastoma Results From the DIRECTOR Trial. Neurosurgery, 2015, 62, 209.	1.1	6
610	Burnout and career satisfaction in neuro-oncology: a survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology memberships. Neuro-Oncology, 2020, 22, 838-850.	1.2	6
611	Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration. Neuro-Oncology Advances, 2021, 3, vdab048.	0.7	6
612	A tumor-promoting role for soluble TÎ²RIII in glioblastoma. Molecular and Cellular Biochemistry, 2021, 476, 2963-2973.	3.1	6

#	Article	IF	Citations
613	MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.. Journal of Clinical Oncology, 2014, 32, 2015-2015.	1.6	6
614	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2019, 37, TPS2072-TPS2072.	1.6	6
615	Interferonâ€Î² sensitizes human glioblastoma cells to the cyclinâ€dependent kinase inhibitor, TG02. Oncology Letters, 2020, 19, 2649-2656.	1.8	6
616	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcomeâ€"including in elderly patients. Acta Neuropathologica Communications, 2022, 10, 39.	5.2	6
617	Hemodynamic Imaging in Cerebral Diffuse Gliomaâ€"Part A: Concept, Differential Diagnosis and Tumor Grading. Cancers, 2022, 14, 1432.	3.7	6
618	New insights into acquired temozolomide resistance in glioblastoma?. Brain, 2015, 138, 3468-3470.	7.6	5
619	Evidence-based management of adult patients with diffuse glioma â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e430-e431.	10.7	5
620	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e709-e710.	10.7	5
621	Next generation neuro-oncology. European Journal of Cancer, 2018, 96, 1-5.	2.8	5
622	ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. Neuro-Oncology, 2019, 21, vi14-vi14.	1.2	5
623	Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. Neuro-Oncology Practice, 2020, 7, 668-675.	1.6	5
624	Hemodynamic investigation of peritumoral impaired blood oxygenation-level dependent cerebrovascular reactivity in patients with diffuse glioma. Magnetic Resonance Imaging, 2020, 70, 50-56.	1.8	5
625	Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome. Cancers, 2021, 13, 2934.	3.7	5
626	GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2020, 38, TPS2579-TPS2579.	1.6	5
627	Brain metastasis research: a late awakening. Chinese Clinical Oncology, 2015, 4, 17.	1.2	5
628	A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. Swiss Medical Weekly, 2020, 150, w20256.	1.6	5
629	Hemodynamic Imaging in Cerebral Diffuse Gliomaâ€"Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions. Cancers, 2022, 14, 1342.	3.7	5
630	Opportunities and challenges for the development of â€œcore outcome setsâ€•in neuro-oncology. Neuro-Oncology, 2022, 24, 1048-1055.	1.2	5

#	Article	IF	Citations
631	Reply. Annals of Neurology, 1998, 44, 426-426.	5.3	4
632	Movement disorders reveal Creutzfeldtâ€“Jakob disease. Nature Reviews Neurology, 2009, 5, 185-186.	10.1	4
633	Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!. Journal of Clinical Oncology, 2016, 34, 1829-1830.	1.6	4
634	An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery. Journal of Visualized Experiments, 2016, , .	0.3	4
635	In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study. Journal of Sleep Research, 2019, 28, e12721.	3.2	4
636	Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. Translational Oncology, 2020, 13, 100852.	3.7	4
637	Antidepressant drug use in glioblastoma patients: an epidemiological view. Neuro-Oncology Practice, 2020, 7, 514-521.	1.6	4
638	Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma. Med, 2021, 2, 450-452.	4.4	4
639	Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial.. Journal of Clinical Oncology, 2015, 33, 2041-2041.	1.6	4
640	Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21. Antibodies, 2022, 11, 19.	2.5	4
641	Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 29-44.	2.0	4
642	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. Neuro-Oncology, 2019, 21, vi12-vi12.	1.2	3
643	Impaired speed-dependent modulation of the gait pattern in multiple sclerosis. Journal of Neurology, 2020, 267, 2998-3007.	3.6	3
644	Interferon-Î² exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. Neuro-Oncology Advances, 2020, 2, vdaa043.	0.7	3
645	Distinct Cerebrovascular Reactivity Patterns for Brain Radiation Necrosis. Cancers, 2021, 13, 1840.	3.7	3
646	Fitness-to-drive for glioblastoma patients. Swiss Medical Weekly, 2021, 151, w20501.	1.6	3
647	Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. , 1998, 79, 640.		3
648	MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial.. Journal of Clinical Oncology, 2012, 30, 2000-2000.	1.6	3

#	Article	IF	Citations
649	Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.. Journal of Clinical Oncology, 2014, 32, 2017-2017.	1.6	3
650	Long-term survival in patients with primary CNS lymphoma: Results from the G-PCNSL-SG1 trial.. Journal of Clinical Oncology, 2015, 33, 2032-2032.	1.6	3
651	EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2042-2042.	1.6	3
652	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. Journal of Clinical Oncology, 2019, 37, 2056-2056.	1.6	3
653	Novel cases of amyotrophic lateral sclerosis after treatment of cerebral arteriovenous malformationss. Swiss Medical Weekly, 2016, 146, w14361.	1.6	3
654	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. Journal of Clinical Oncology, 2013, 31, LBA2009-LBA2009.	1.6	3
655	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. Clinical Cancer Research, 2022, 28, 2440-2448.	7.0	3
656	m6A Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes. Frontiers in Oncology, 2021, 11, 760892.	2.8	3
657	Prognosis of walking function in multiple sclerosis supported by gait pattern analysis. Multiple Sclerosis and Related Disorders, 2022, 63, 103802.	2.0	3
658	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2022, 40, TPS2078-TPS2078.	1.6	3
659	Prime time for molecular marker diagnostics in neuro-oncology. Current Opinion in Neurology, 2012, 25, 743-744.	3.6	2
660	ACTR-30. EORTC 1608: AÂPHASE 1B STUDY OF TG02, AN ORAL CYCLIN-DEPENDENT KINASE 9/5 INHIBITOR, IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA STRATIFIED BY MGMT PROMOTER METHYLATION STATUS. Neuro-Oncology, 2016, 18, vi8-vi8.	1.2	2
661	Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 2016, 34, 3107-3108.	1.6	2
662	Reply to glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer, 2016, 122, 3740-3741.	4.1	2
663	Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. Public Health Genomics, 2016, 19, 170-177.	1.0	2
664	Meeting Updateâ€"World Federation of Neuro-Oncology Societies (WFNOS) Meeting 2017. Neuro-Oncology, 2017, 19, 1457-1459.	1.2	2
665	ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM). Neuro-Oncology, 2018, 20, vi4-vi4.	1.2	2
666	Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. Journal of Neurosurgery, 2018, 129, 1104-1105.	1.6	2

#	Article	IF	Citations
667	LTBK-12. EORTC 26951, RANDOMIZED STUDY OF ADJUVANT PCV AFTER 59.4 GY RADIOTHERAPY: VERY LONG TERM FOLLOW-UP. Neuro-Oncology, 2019, 21, vi285-vi285.	1.2	2
668	The molecular evolution of glioblastoma treated by gross total resection alone. Neuro-Oncology, 2021, 23, 334-336.	1.2	2
669	Pathway-based stratification of glioblastoma. Nature Reviews Neurology, 2021, 17, 263-264.	10.1	2
670	Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. Molecular Therapy - Oncolytics, 2021, 20, 166-174.	4.4	2
671	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2074-TPS2074.	1.6	2
672	Radiotherapy for glioblastoma patients with poor performance status. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2127-2136.	2.5	2
673	Adjuvant Therapy. Recent Results in Cancer Research, 2009, 171, 141-153.	1.8	2
674	Bevacizumab failure in glioblastomas.. Journal of Clinical Oncology, 2012, 30, 2067-2067.	1.6	2
675	Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 2092-2092.	1.6	2
676	G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up.. Journal of Clinical Oncology, 2014, 32, 8527-8527.	1.6	2
677	Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009).. Journal of Clinical Oncology, 2015, 33, e13025-e13025.	1.6	2
678	Correlation of IDH mutation, 1p/19q co-deletion and 18FET-PET derived time-to-peak analysis as prognostic markers in glioma. Journal of Clinical Oncology, 2016, 34, 2058-2058.	1.6	2
679	Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group.. Journal of Clinical Oncology, 2020, 38, 2521-2521.	1.6	2
680	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. Hematology/Oncology Clinics of North America, 2021, 36, 113-132.	2.2	2
681	Prognostic Relevance of Transforming Growth Factor-Î² Receptor Expression and Signaling in Glioblastoma, Isocitrate Dehydrogenase-Wildtype. Journal of Neuropathology and Experimental Neurology, 2022, 81, 225-235.	1.7	2
682	Mid-term treatment-related cognitive sequelae in glioma patients. Journal of Neuro-Oncology, 2022, 159, 65-79.	2.9	2
683	â€œNanomaniaâ€•ante portas of neurooncology?. Journal of Neuro-Oncology, 2011, 104, 613-614.	2.9	1
684	Microglia: a novel treatment target in gliomas. Neuro-Oncology, 2012, 14, 957-957.	1.2	1

#	Article	IF	Citations
685	Elderly people with glioblastoma â€“ Authors' reply. Lancet Oncology, The, 2012, 13, e329.	10.7	1
686	Brain Tumor Imaging. Medical Radiology, 2015, , 1-9.	0.1	1
687	ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v12.2-v12.	1.2	1
688	BMET-18. DIAGNOSIS AND TREATMENT PATTERNS FOR PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS ACROSS EUROPE. Neuro-Oncology, 2016, 18, vi30-vi30.	1.2	1
689	ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL. Neuro-Oncology, 2016, 18, vi1-vi2.	1.2	1
690	IMMU-53. IMPACT OF TUMOR-TREATING FIELDS (TTFIELDS) ON THE IMMUNOGENICITY OF GLIOMA CELLS. Neuro-Oncology, 2018, 20, vi133-vi133.	1.2	1
691	RARE-19. CHEMOTHERAPY FOR SPINAL GLIOMAS IN ADULTS: A RETROSPECTIVE STUDY. Neuro-Oncology, 2018, 20, vi240-vi240.	1.2	1
692	CMET-39. INTRA-CSF LIPOSOMAL CYTARABINE PLUS SYSTEMIC THERAPY AS INITIAL TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS: A RANDOMISED, OPEN-LABEL TRIAL. Neuro-Oncology, 2018, 20, vi61-vi62.	1.2	1
693	ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUXâ€“M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE		

#	Article	IF	Citations
703	Prognostic value of ¹⁸FET positron emission tomography (¹⁸FET-PET) for the clinical course in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2045-2045.	1.6	1
704	Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers.. Journal of Clinical Oncology, 2013, 31, 2059-2059.	1.6	1
705	Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling.. Journal of Clinical Oncology, 2015, 33, 2007-2007.	1.6	1
706	Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network.. Journal of Clinical Oncology, 2017, 35, 2038-2038.	1.6	1
707	Barriers to accrual and enrollment in brain tumor trials.. Journal of Clinical Oncology, 2019, 37, 2024-2024.	1.6	1
708	The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery.. Journal of Clinical Oncology, 2020, 38, 3128-3128.	1.6	1
709	Role of Integrins in Angiogenesis. , 2013, , 79-91.		1
710	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, e14070-e14070.	1.6	1
711	Single cell mapping of human brain tumors reveals tumor-specific education of tissue-invading leukocytes.. Journal of Clinical Oncology, 2020, 38, 2509-2509.	1.6	1
712	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. Neuro-Oncology Advances, 2020, 2, vdaa147.	0.7	1
713	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. Neuro-Oncology, 2021, 23, vi126-vi127.	1.2	1
714	Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.7	1
715	Effective suppression of crescendo amaurosis fugax associated with anti-phospholipid antibodies by low dose aspirin. Neuro-Ophthalmology, 1991, 11, 195-197.	1.0	0
716	Apoptosis Pathways and Chemotherapy. , 2006, , 141-154.		0
717	Molekular definierte Chemotherapien und zielgerichtete Therapien bei malignen Gliomen. Onkopipeline, 2008, 1, 11-16.	0.0	0
718	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2010, 28, e696-e697.	1.6	0
719	Clinical trials in neuro-oncology. Current Opinion in Neurology, 2011, 24, 597-598.	3.6	0
720	ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERSâ€™ COLLABORATIVE CONSORTIUM. Neuro-Oncology, 2016, 18, vi5-vi5.	1.2	0

#	Article	IF	Citations
721	Reply: Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. Brain, 2016, 140, aww325.	7.6	0
722	HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2016, 18, iii63.2-iii63.	1.2	0
723	DRES-13. EXTENDED TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK. Neuro-Oncology, 2016, 18, vi54-vi54.	1.2	0
724	ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERSâ€™ COLLABORATIVE CONSORTIUM. Neuro-Oncology, 2017, 19, vi5-vi6.	1.2	0
725	ACTR-53. STEAM / EORTC 1608: STUDY OF TG02 IN ELDERLY NEWLY DIAGNOSED OR ADULT RELAPSED PATIENTS WITH ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA - A PHASE 1B STUDY. Neuro-Oncology, 2018, 20, vi23-vi24.	1.2	0
726	RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi235-vi236.	1.2	0
727	PATH-51. DNA COPY NUMBER PROFILING ACROSS GLIOBLASTOMA POPULATIONS HAS IMPLICATIONS FOR CLINICAL TRIAL DESIGN. Neuro-Oncology, 2018, 20, vi169-vi170.	1.2	0
728	QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS?. Neuro-Oncology, 2018, 20, vi221-vi221.	1.2	0
729	ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL. Neuro-Oncology, 2018, 20, vi22-vi22.	1.2	0
730	CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi48-vi49.	1.2	0
731	CSIG-26. MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi48-vi48.	1.2	0
732	ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL. Neuro-Oncology, 2018, 20, vi25-vi25.	1.2	0
733	ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL. Neuro-Oncology, 2018, 20, vi14-vi14.	1.2	0
734	CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY. Neuro-Oncology, 2018, 20, vi59-vi59.	1.2	0
735	MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE. Neuro-Oncology, 2018, 20, vi151-vi151.	1.2	0
736	MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE. Neuro-Oncology, 2018, 20, vi148-vi149.	1.2	0
737	QOLP-27. USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN GLIOMA PATIENTS. Neuro-Oncology, 2018, 20, vi220-vi220.	1.2	0
738	MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA. Neuro-Oncology Advances, 2019, 1, i17-i17.	0.7	0

#	Article	IF	Citations
739	Challenges in the diagnoses and treatment of CNS tumors. Neuro-Oncology Practice, 2019, 6, 329-329.	1.6	0
740	Concepts of Personalized Medicine in Neuro-oncology. , 2019, , 153-158.		0
741	Glioblastoma. , 2019, , 237-247.		0
742	Basics of Brain Tumor Biology for Clinicians. , 2019, , 7-19.		0
743	CSIG-06. DEPATUXIZUMAB MAFODOTIN (ABT-414)-INDUCED GLIOBLASTOMA CELL DEATH REQUIRES EGFR OVEREXPRESSION, BUT NOT PHOSPHORYLATION. Neuro-Oncology, 2019, 21, vi45-vi45.	1.2	0
744	EPID-10. VENOUS THROMBOEMBOLIC EVENTS IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW. Neuro-Oncology, 2019, 21, vi76-vi76.	1.2	0
745	DDIS-04. INTERFERON-Î² SENSITIZES HUMAN GLIOBLASTOMA CELLS TO THE CYCLIN-DEPENDENT KINASE INHIBITOR, TG02. Neuro-Oncology, 2019, 21, vi65-vi66.	1.2	0
746	CBMT-12. FOCAD LOSS IMPACTS MICROTUBULE ASSEMBLY, G2/M PROGRESSION AND PATIENT SURVIVAL IN ASTROCYTIC GLIOMAS. Neuro-Oncology, 2019, 21, vi35-vi35.	1.2	0
747	IMMU-17. TARGETING GLIOBLASTOMA WITH DNAM-1-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS. Neuro-Oncology, 2019, 21, vi122-vi122.	1.2	0
748	IMMU-08. THE ANTIGENIC LANDSCAPE OF GLIOBLASTOMA - REFINING THE TARGETS FOR IMMUNOTHERAPY. Neuro-Oncology, 2019, 21, vi120-vi120.	1.2	0
749	QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING. Neuro-Oncology, 2019, 21, vi198-vi198.	1.2	0
750	Important themes in Neuro-Oncology Practice: Rare brain tumors, radiotherapy and its side effects, and supportive and palliative care. Neuro-Oncology Practice, 2020, 7, 357-358.	1.6	0
751	Prognostic value of O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. Acta OncolÃ³gica, 2020, 59, 1357-1364.	1.8	0
752	42. IDENTIFICATION OF BRAIN METASTASIS VULNERABILITIES USING METPLATFORM. Neuro-Oncology Advances, 2020, 2, ii8-ii8.	0.7	0
753	DEPOSEINâ€"how meaningful was the benefit from intrathecal chemotherapy?. Neuro-Oncology, 2020, 22, 1710-1711.	1.2	0
754	Kindliche Hirntumoren bei Erwachsenen: Medulloblastom. Springer Reference Medizin, 2021, , 1-8.	0.0	0
755	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. Neuro-Oncology, 2021, 23, 506-507.	1.2	0
756	Prognostic factors in leptomeningeal metastases. Neuro-Oncology, 2021, 23, 1208-1209.	1.2	0

#	Article	IF	Citations
757	Digital measurement of functional status of patients with glioblastoma.. Journal of Clinical Oncology, 2021, 39, 2016-2016.	1.6	0
758	SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine. Neuro-Oncology Advances, 2021, 3, iii25-iii25.	0.7	0
759	BSCI-02. METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy. Neuro-Oncology Advances, 2021, 3, iii1-iii1.	0.7	0
760	SYST-03. A PHASE I/II STUDY TO EVALUATE SAFETY AND PRELIMINARY ACTIVITY OF THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF IN PATIENTS WITH GLIOBLASTOMA AT FIRST RELAPSE. Neuro-Oncology Advances, 2021, 3, iv8-iv9.	0.7	0
761	New Glioma Molecular Classification for Precise Therapeutic Decision Based on Spatially-Resolved Proteogenomics Guided by MALDI-MSI and Clinical Data Integration. SSRN Electronic Journal, 0, , .	0.4	0
762	Death Ligand/Death Receptor-Mediated Apoptosis for Treatment of Brain Tumors. , 2001, , 327-344.		0
763	Modulating TGF-Î² Receptor Signaling: A Novel Approach of Cancer Therapy. , 2008, , 653-669.		0
764	Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-SG-1 trial.. Journal of Clinical Oncology, 2012, 30, 2007-2007.	1.6	0
765	Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations.. Journal of Clinical Oncology, 2013, 31, 2027-2027.	1.6	0
766	Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).. Journal of Clinical Oncology, 2013, 31, TPS2103-TPS2103.	1.6	0
767	Effect of silencing thymosin beta 4 gene expression on stemness and invasiveness in glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2081-2081.	1.6	0
768	Induction of atypical anoikis in glioma cells through inhibition of integrin functions.. Journal of Clinical Oncology, 2013, 31, 2079-2079.	1.6	0
769	Hirntumoren. , 2015, , 609-619.		0
770	Intravenous vs. intra-arterial methotrexate-based chemotherapy regimens for newly diagnosed primary central nervous system lymphoma.. Journal of Clinical Oncology, 2016, 34, e13505-e13505.	1.6	0
771	The value of ¹⁸F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. Journal of Clinical Oncology, 2017, 35, 2076-2076.	1.6	0
772	Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A systematic review and meta-analysis of numbers needed to treat.. Journal of Clinical Oncology, 2017, 35, 2057-2057.	1.6	0
773	Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2013-2013.	1.6	0
774	Sensitization of glioblastoma to alkylating chemotherapy by ultrasound-mediated delivery of therapeutic liposomes.. Journal of Clinical Oncology, 2018, 36, e14061-e14061.	1.6	0

#	Article	IF	Citations
775	Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2042-2042.	1.6	0
776	Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. Journal of Clinical Oncology, 2018, 36, e14062-e14062.	1.6	0
777	Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study. , 2019, 80, .		0
778	Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. Journal of Clinical Oncology, 2019, 37, 2013-2013.	1.6	0
779	Treatment of Leptomeningeal Metastases. , 2020, , 301-311.		0
780	CNS Tumors in Older Adults. , 2020, , 813-821.		0
781	Tumors: Brain. , 2020, , 1-8.		0
782	Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death.. Journal of Clinical Oncology, 2020, 38, e14530-e14530.	1.6	0
783	Gliome des Erwachsenenalters. Springer Reference Medizin, 2021, , 1-12.	0.0	0
784	CSIG-17. IMMUNE MODULATORY ROLE OF TYPE I INTERFERON IN SYNGENEIC MOUSE GLIOMA MODELS. Neuro-Oncology, 2021, 23, vi36-vi37.	1.2	0
785	DDRE-21. LOMUSTINE AND TARGETED-CYTOKINE THERAPY: A BENEFICIAL LIAISON FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi78-vi79.	1.2	0
786	EPCO-09. LONGITUDINAL ANALYSIS OF DIFFUSE GLIOMA REVEALS CELL STATE DYNAMICS AT RECURRENCE ASSOCIATED WITH CHANGES IN GENETICS AND THE MICROENVIRONMENT. Neuro-Oncology, 2021, 23, vi3-vi3.	1.2	0
787	IMMU-13. COMBINED MODULATION OF THE TGF-Î² PATHWAY AND GITR IMMUNE CHECKPOINT SIGNALING PROMOTES ANTI-TUMOR IMMUNITY IN SYNGENEIC GLIOMA MODELS. Neuro-Oncology, 2021, 23, vi94-vi94.	1.2	0
788	IMMU-39. EVALUATION OF CD317-TARGETING CAR T CELLS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY AGAINST GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi101-vi101.	1.2	0
789	EXTH-21. MECHANISMS OF SYNERGISTIC GROWTH SUPPRESSION BY RADIOTHERAPY AND C-MET INHIBITION IN EXPERIMENTAL GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi167-vi168.	1.2	0
790	CSIG-22. Cd95l/Cd95 GENE DELETION DECREASES MOUSE GLIOMA TUMORIGENESIS THROUGH THE INHIBITION OF NON-CANONICAL CD95L/CD95-MEDIATED CELL GROWTH AND IMMUNOSUPPRESSION. Neuro-Oncology, 2021, 23, vi37-vi38.	1.2	0
791	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. Neuro-Oncology, 2021, 23, vi123-vi124.	1.2	0
792	Tumors: Brain. , 2021, , 5208-5215.		0

#	Article	IF	Citations
793	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2055-2055.	1.6	0
794	Abstract 5325: Image-based functional precision medicine for repurposing neuroactive drugs in glioblastoma. Cancer Research, 2022, 82, 5325-5325.	0.9	0
795	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.. Journal of Clinical Oncology, 2022, 40, 2026-2026.	1.6	0